New drugs cause atrophy of cancer tumors

Drugs can attack cells and cause them to shrink.

According to Newsweek, scientists have created a new drug that can attack ovarian cancer and lung cancer cells in patients whose other treatments have failed. The study was carried out by scientists at the Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust, and research groups of 9 organizations across the UK.

A woman with cancer is in the process of treatment.

The researchers combined a new drug called vistusertib with paclitaxel chemotherapy drug. They tested 25 women with ovarian cancer and 40 lung cancer patients. These patients are unresponsive to standard treatment and cancer has spread throughout the body.

As a result, more than half of ovarian cancer patients and one third of lung cancer patients see their tumors shrink. Drugs prevent the development of cancer for nearly 6 months.

Ovarian cancer cells usually have a higher p-S6K molecular level. This is a disease-causing molecule. The drug, when combined with paclitaxel chemotherapy, can penetrate molecules that cause cancer and block them, making the tumor unable to grow.

A second phase trial study on a larger model, with 140 women with recurrent ovarian cancer, treated with standard chemotherapy (paclitaxel) in combination with vistusertib. The results are expected to be published at the end of the year."To see how this approach works compared to chemotherapy alone ," the researchers said.

Dr. Susana Banerjee commented: 'This is a very encouraging result when the current medical techniques for treating cancer are limited.' She is "particularly surprised" by the effect of the reaction between vistusertib combined. With paclitaxel, closely related to standard chemotherapy, effective testing for patients with ovarian and lung cancer, scientists will expand the study with other cancers.